In studies conducted before the identification of SMARCB1 mutations with consecutive loss of INI1-positivity in immunohistochemistry, the classification of liver tumors as MRTL were solely based on cytomorphology (i.e., predominance of rhabdoid tumor cells). The gene discussed is SMARCB1; the disease is neoplasm.